Our Partners
We selectively partner our programs in order to accelerate timelines and better align resources.
Theravance Biopharma has developed YUPELRI® (revefenacin) inhalation solution, under a strategic collaboration with Viatris. Viatris and Theravance Biopharma co-commercialize the product in the United States.
REV-2021-0087
See our latest SEC filings for further details on our partnerships.